| 常伟,周建华,张明雷,孟凡华,刘素风,冯文娜.胸苷酸合成酶与结直肠癌患者FOLFOX方案化疗预后的相关性分析.[J].中南医学科学杂志.,2017,(1):81-84. |
| 胸苷酸合成酶与结直肠癌患者FOLFOX方案化疗预后的相关性分析 |
| Association between thymidylate synthase and short and medium term prognosis of FOLFOX chemotherapy in colorectal cancer |
| 投稿时间：2017-07-10 修订日期：2017-12-30 |
| DOI：10.15972/j.cnki.43-1509/r.2017.01.020 |
| 中文关键词: 胸苷酸合成酶 结直肠癌 5-氟尿嘧啶 |
| 英文关键词:thymidylate synthase (TS) colorectal cancer 5-fluorouracil |
| 基金项目: |
| 作者 | 单位 | | 常伟 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 | | 周建华 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 | | 张明雷 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 | | 孟凡华 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 | | 刘素风 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 | | 冯文娜 | 新乡医学院附属人民医院,新乡市第一人民医院肿瘤科,河南 新乡 453000 |
|
| 摘要点击次数: 847 |
| 全文下载次数: 584 |
| 中文摘要: |
| 目的 探讨生物标志物胸苷酸合成酶(TS)基因表达与FOLFOX方案化疗后结直肠癌患者短中期预后的关系。方法 纳入本院收治的116例结直肠癌患者,使用改良FOLFOX6(mFOLFOX6)或改良FOLFOX7(mFOLFOX7)方案治疗12疗程后随访1~3年,比较TS的阳性、阴性表达患者的疗效、安全性和3年总生存率。结果 TS+和TS-患者的疗效分布间差异有显著性(χ2=10.510,P=0.015)；TS+和TS-患者的恶心呕吐(χ2=18.644,P<0.001)、腹泻(χ2=16.518,P<0.001)和口腔黏膜炎(χ2=23.344,P<0.001)发生的严重程度分布差异有统计学意义；TS+患者的3年总生存率为38.3%,而TS-为31.4%(Log rank χ2=6.417,P=0.011,HR=1.784,5%CI:1.084～2.936)。结论 TS基因表达情况对结直肠癌患者接受FOLFOX方案化疗的疗效和安全性具有一定预测作用,其中TS还可预测患者中期生存情况。 |
| 英文摘要: |
| Objective To investigate the association between the gene expression of thymidylate synthase (TS) and short mid-term prognosis of FOLFOX chemotherapy in colorectal cancer.Methods 116 patients with colorectal cancer treated during May 2013 to April 2015 in our hospital were included.A modified FOLFOX6 (mFOLFOX6) or FOLFOX7 (mFOLFOX7) program was used for 12 cycles,followed up for 1~3 years,then curative effect,safety,and 3-year overall survival rate of TS positive,negative expression of patients were compared.Results The distribution of efficacy for patients with TS+ and TS- had significant difference (χ2=10.510,P=0.015); the severity of nausea and vomiting (χ2=18.644,P<0.001),diarrhea (χ2=16.518,P<0.001) and oral mucositis (χ2=23.344,P<0.001) in TS + and TS- patients had significant difference; 3-year overall survival rate in patients with TS+ and TS- were 38.3% and 31.4%,respectively,the difference between the two groups was significant (Log rank χ2=6.417,P=0.011,HR=1.784,5%CI:1.084～2.936).Conclusion Gene expression of TS had some predictive values in the efficacy and safety in patients with colorectal cancer received FOLFOX chemotherapy,in which TS could predict patient’s medium term survival. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|